Blueprint Medicines

🇺🇸 NASDAQ:BPMC

Overview

Earnings Dividends Seasonality Metrics

SEP

9

Q2 2025

Reported

Reported earnings 4 months ago

Total Revenue

$149M

Previous year: $96.1M

+55.5%

EPS

$0.01

Previous year: -$1.32

-100.8%

R&D Expenses

$91.9M

Previous year: $88.2M

+4.2%

SG&A Expenses

$95.8M

Previous year: $83.6M

+14.7%

Total Cost and Operating Expenses

Previous year: $1.04B

+15.1%

Loading...

Blueprint Medicines

Unlock previous datapoints

Upgrade

Blueprint Medicines

Unlock previous datapoints

Upgrade

Blueprint Medicines Revenue by Segment

Blueprint Medicines Revenue by Geographic Location

Revenue by Segment

Product Revenue, Net Revenue

CapyFin.com

Revenue by Geographic Location

US Revenue

CapyFin.com

Ex-US Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$8.37B

P/E Ratio

-52.41

Sector

N/A

Industry

N/A

52-Week High

$129

52-Week Low

$79.1

R&D Expenses

$91.9M

SG&A Expenses

$95.8M

Total Cost and Operating Expenses

$190M

Interest Expense, Net

-$8.13M

Other Income, Net

$461K

Products

Get in Touch

Resources

Blueprint Medicines

Blueprint Medicines

Blueprint Medicines Revenue by Segment

Blueprint Medicines Revenue by Geographic Location

Revenue by Segment

Product Revenue, Net Revenue

Revenue by Geographic Location

US Revenue

Ex-US Revenue

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics